News Channels

14 Feb 2019 Addex and Indivior to Accelerate Additional GABAB PAM Compounds for Addiction as Indivior Elects to Stop Development of ADX71441
14 Feb 2019 Codexis Announces Nestlé Health Science Exercises Option for Exclusive Global License to CDX-6114 for the Management of Phenylketonuria
14 Feb 2019 DiaMedica Therapeutics Doses First Patient in Phase 1b Clinical Study of DM199 in Patients with Chronic Kidney Disease
14 Feb 2019 Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission
14 Feb 2019 Debiopharm International SA Initiates FUZE, a Clinical Trial Phase II Study Evaluating Debio 1347 in Advanced Solid Tumors Harboring an FGFR fusion
14 Feb 2019 Sarepta Announces FDA Acceptance of Golodirsen (SRP-4053) New Drug Application for Patients with Duchenne Muscular Dystrophy Amenable to Skipping Exon 53
14 Feb 2019 Motif Bio Receives Complete Response Letter from the FDA
14 Feb 2019 Lundbeck and Otsuka report phase III data evaluating brexpiprazole for the treatment of manic episodes associated with bipolar I disorder
14 Feb 2019 Novartis receives FDA approval for Egaten® for the treatment of fascioliasis, a neglected tropical disease
13 Feb 2019 ADC Therapeutics Announces First Patient Dosed in Phase I Clinical Trial of ADCT-402 (loncastuximab tesirine) and IMFINZI® (durvalumab) in Multiple Types of Advanced Non-Hodgkin Lymphoma
13 Feb 2019 Clinigen to acquire US rights to Proleukin
13 Feb 2019 Moderna Announces Positive Interim Phase 1 Data for First Combination Vaccine Against the Respiratory Viruses hMPV and PIV3
13 Feb 2019 Exelixis to Initiate Phase 1 Clinical Development of XL092, First New Compound to Enter the Clinic from Reinitiated Discovery Efforts
13 Feb 2019 Affinivax, Inc. Announces Initiation of Phase 1/2 Clinical Study of ASP3772, Its Novel Pneumococcal MAPS Vaccine, in Collaboration with Astellas
13 Feb 2019 Sojournix Announces Positive Top-Line Phase 1 Data Demonstrating Clinical Proof of Mechanism and Once-Daily (QD) Pharmacokinetics for SJX-653
13 Feb 2019 BioArctic's Product Candidate SC0806 for Treatment of Patients With Complete Spinal Cord Injury is now in Phase 2
13 Feb 2019 Summit Doses First Patient in Phase 3 Clinical Trials of Precision Antibiotic Ridinilazole for C. Difficile Infection
12 Feb 2019 Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts
12 Feb 2019 Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
12 Feb 2019 Ascendis Pharma Initiates Global Phase 2 Trial for TransCon PTH in Adult Subjects with Hypoparathyroidism

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up